Drug Trial Radar · NCT06870422
To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.
Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Feb 28, 2025
Primary completion
Apr 3, 2025
Study completion Apr 14, 2025
Sponsor
- Lead sponsor
- Teikoku Seiyaku Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH
- First posted
- Mar 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, single-dose trial performed in a randomized, four-way, change-over design in healthy volunteers. The primary purpose of this study is to evaluate the effect of moderate heat, occlusion, and moderate exercise on pharmacokinetics. The secondary purpose is to characterize the effect of special conditions on the bioavailability and to evaluate patch adhesion and safety of TK-254RX and a residual amount of the patch.
Conditions
- Healthy
Interventions
Esflurbiprofen Topical SystemDrug
TK-254RX will be applied for one day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessing the effect of each intervention by Area under the plasma concentration versus time curve over 24 hours (AUC0-24) of S-flurbiprofenTime frame: Day 1 to Day 2 for each period
- Assessing the effect of each intervention by peak plasma concentration (Cmax) of S-flurbiprofenTime frame: Day 1 to Day 2 for each period
- Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to last measurement time point with a concentration value above lower limit of quantitation (AUC0-tlast) of S-flurbiprofenTime frame: Day 1 to Day 4 for each period
- Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to infinity (AUC0-inf) of S-flurbiprofenTime frame: Day 1 to Day 4 for each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SocraTec R&D GmbH Clinical Pharmacology Unit
Mainzerhofplatz, Erfurt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.